Revive Therapeutics Provides Corporate Update
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Brain
Brainbot Selected for Techstars Healthcare Accelerator Class of 2024
The Canadian startup has gained exclusive access to the U.S. accelerator, including funding, resources, and engagement with world-renowned health organizationsTORONTO--(BUSINESS...
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / March 11, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested;...
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD...
“LUKi & The Lights” Animated Short Film Illuminates ALS Diagnosis for Young Audiences
Global Premiere Set for March 22 at Cinema Village in Greenwich Village, NYC ARLINGTON, Va., March 7, 2024 /PRNewswire/ --...
Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first...
Does Iron Accumulate in Brain After Concussions?
MINNEAPOLIS, March 7, 2024 /PRNewswire/ -- People who have headaches after experiencing concussions may also be more likely to have...
Masimo Celebrates Multiple Wins at the iF DESIGN AWARDS 2024
Masimo Stork™ and Bowers & Wilkins Garner Six Prestigious Accolades Across Multiple CategoriesIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) is proud to...
Onsite Launches Outpatient Services at Onsite Wellness House in Nashville
Onsite Wellness House brings the best of Onsite and Milestones to those in Nashville and surrounding areas while minimizing disruption...
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses...
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of...
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer’s Conference
STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
We Heart You: Recovery in Our Community Event 2024
What: We Heart You: Recovery in Our Community EventWhen: Wednesday, March 13, 12:00-5:00 PM(Welcome at 12:30 PM, Keynote speaker from...
Zeto Adds New Chief Financial Officer to Accelerate Growth
SANTA CLARA, CA / ACCESSWIRE / March 6, 2024 / Zeto, Inc., a commercial-stage medical technology company transforming EEG brain...
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,...
Nalu Medical, Inc. Closes $85 Million Series E Round
B Capital invests incremental $20M; previously raised $65M led by Novo Holdings with participation from existing investors Equity investment to...
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be testedChronic dosing over a 12-week treatment periodWill assess weight loss and blood glucose...